A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
Principal Investigator
Mothaffar Rimawi, MD
Status
Complete
Date Opened To Accrual
January 15 2014
Date Closed to Accrual
June 03 2016
Disease Site
Breast [BR]
Breast
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine whether the addition of estrogen deprivation to neoadjuvant therapy consisting of TCHP yields a greater rate of pCR (breast and nodes) than TCHP alone when administered to women with operable, hormone receptor-positive, HER2-positive breast cancer.
Patient Population
Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer
Target Accrual
312
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.